Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics' stock experienced significant fluctuations in the past six months. On January 8, 2026, the stock surged due to positive Phase 1b data for ELVN-001 in CML, reaching a new 52-week high. Prior to this, the stock had declined. The company reported its Q3 2025 earnings, beating consensus estimates. Insider selling occurred in November, December, and January. The company also bolstered its board in preparation for the next phase of development, including a pivotal Phase 3 trial for ELVN-001.

Enliven Therapeutics' demand is primarily driven by the progression of its drug candidates through clinical trials and eventual market approval, rather than typical consumer demand seasonality. The demand for its potential products would be continuous and based on medical need, not seasonal fluctuations. While a seasonal analysis for ELVN's stock price has been attempted, it is noted that only four years of data are available, which is considered insufficient to create a reliable seasonal profile. However, the Healthcare sector, in general, has a period of seasonal strength from April 25 to December 4.

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to improve outcomes for cancer patients. The company develops kinase inhibitors designed to enhance efficacy, combat resistance, address brain metastases, and improve safety and patient convenience. Its major product candidates include ELVN-001, a kinase inhibitor targeting the BCR-ABL fusion gene for CML, currently in Phase 1 trials and ELVN-002, a CNS penetrant HER2 inhibitor for NSCLC and other HER2-driven solid tumors, also in Phase 1 trials. ELVN-001 has shown activity against the T315I mutation, while ELVN-002 is designed to inhibit wild-type HER2 and various HER2 mutations while sparing wild-type EGFR to avoid related toxicities.

Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado, United States.

Enliven Therapeutics' brand reputation has been influenced by its clinical trial progress and financial performance. Positive Phase 1b data for ELVN-001 significantly boosted the company's standing and stock price. Analyst ratings for ELVN are mixed but lean towards positive, with a consensus rating of "Moderate Buy" and an average target price of $41.00. The company also beat its Q3 2025 earnings estimates, which can contribute positively to its reputation.

Enliven Therapeutics, Inc. has 279 institutional owners and shareholders holding a total of 63,107,919 shares. Institutional ownership accounts for approximately 88.85% of the company, with individuals holding about 4.12%. Hedge funds hold 13.4% and VC/PE firms hold 17.9% of the shares. Major institutional owners include Orbimed Advisors Llc, Fmr Llc, Commodore Capital Lp, Fairmount Funds Management LLC, BlackRock, Inc., VR Adviser, LLC, Polar Capital Holdings Plc, Vanguard Group Inc, Janus Henderson Group Plc and Novo Holdings A/S.